Loading…
Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy
Osteoprotegerin (OPG) has been associated with increased risk and severity of atherosclerotic disease in the general population. Since ankylosing spondylitis (AS) is a chronic inflammatory disease associated with accelerated atherosclerosis, we aimed to assess whether OPG levels correlate with disea...
Saved in:
Published in: | Clinical and experimental rheumatology 2014-09, Vol.32 (5), p.640-646 |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 646 |
container_issue | 5 |
container_start_page | 640 |
container_title | Clinical and experimental rheumatology |
container_volume | 32 |
creator | Genre, Fernanda López-Mejías, Raquel Miranda-Filloy, José A Ubilla, Begoña Carnero-López, Beatriz Palmou-Fontana, Natalia Gómez-Acebo, Inés Blanco, Ricardo Rueda-Gotor, Javier Pina, Trinitario González-Juanatey, Carlos Llorca, Javier González-Gay, Miguel Á |
description | Osteoprotegerin (OPG) has been associated with increased risk and severity of atherosclerotic disease in the general population. Since ankylosing spondylitis (AS) is a chronic inflammatory disease associated with accelerated atherosclerosis, we aimed to assess whether OPG levels correlate with disease activity, systemic inflammation, metabolic syndrome, adipokines and biomarkers of endothelial cell activation in patients with AS undergoing TNF-α antagonist therapy.
We assessed OPG plasma concentration in 30 non-diabetic AS patients without cardiovascular disease undergoing TNF-α antagonist-infliximab therapy. OPG levels were measured immediately before and after an infliximab infusion. Correlations of OPG levels with disease activity, clinical characteristics, systemic inflammation, metabolic syndrome features, adipokines and biomarkers of endothelial activation were assessed. Changes in OPG concentration following an infusion of anti-TNF-α monoclonal antibody-infliximab were also analysed.
We found a positive correlation between OPG levels and markers of disease activity such as BASDAI and VAS spinal pain (r=0.497, p=0.01; r=0.390; p=0.04, respectively). No differences in OPG levels according to specific clinical features of the disease were seen. An inverse correlation between OPG levels and total cholesterol and LDL-cholesterol was also found (r=-0.451; p=0.02 and r=-0.411; p=0.03, respectively). A correlation between OPG and asymmetric dimethylarginine, a biomarker of endothelial cell activation, was also disclosed (r=0.533; p=0.01). No correlation between OPG level and insulin resistance was observed. An infliximab infusion did not lead to a significant reduction in OPG levels.
OPG shows a correlation with markers of disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1586103763</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1586103763</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-c74200951bdf87b92666daebf48f7ff6f33e01a4fc9221a90af541d0790207643</originalsourceid><addsrcrecordid>eNo1kE1OwzAUhLMA0VK4AvKSTST_JE6yRBUFJEQ3RWIXvcTPqcG1Q-yCchuuwEU4E0Etq1nM981iTpI5FRVPy1y-zJLzEF4p5TKXxVky4zmraJaLefK1DhF9P_iIHQ7GkdYPA1qIGMiniVuiTEAISKCN5sPEkYBTBJ3ycYvWgD0UEI13ZNKdd6ky0GA07YS-jdYH4zoSeu_UaE00gfQTjS4GsncKh87_9ZunVfrzPRkROu9MiGTaH6AfL5JTDTbg5TEXyfPqdrO8Tx_Xdw_Lm8e054zFtC0yTmmVs0bpsmgqLqVUgI3OSl1oLbUQSBlkuq04Z1BR0HnGFC0qymkhM7FIrg-70xfvewyx3pnQorXg0O9DzfJSMioKKSb06ojumx2quh_MDoax_n9V_AK7_Xhe</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1586103763</pqid></control><display><type>article</type><title>Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy</title><source>Freely Accessible Journals</source><creator>Genre, Fernanda ; López-Mejías, Raquel ; Miranda-Filloy, José A ; Ubilla, Begoña ; Carnero-López, Beatriz ; Palmou-Fontana, Natalia ; Gómez-Acebo, Inés ; Blanco, Ricardo ; Rueda-Gotor, Javier ; Pina, Trinitario ; González-Juanatey, Carlos ; Llorca, Javier ; González-Gay, Miguel Á</creator><creatorcontrib>Genre, Fernanda ; López-Mejías, Raquel ; Miranda-Filloy, José A ; Ubilla, Begoña ; Carnero-López, Beatriz ; Palmou-Fontana, Natalia ; Gómez-Acebo, Inés ; Blanco, Ricardo ; Rueda-Gotor, Javier ; Pina, Trinitario ; González-Juanatey, Carlos ; Llorca, Javier ; González-Gay, Miguel Á</creatorcontrib><description>Osteoprotegerin (OPG) has been associated with increased risk and severity of atherosclerotic disease in the general population. Since ankylosing spondylitis (AS) is a chronic inflammatory disease associated with accelerated atherosclerosis, we aimed to assess whether OPG levels correlate with disease activity, systemic inflammation, metabolic syndrome, adipokines and biomarkers of endothelial cell activation in patients with AS undergoing TNF-α antagonist therapy.
We assessed OPG plasma concentration in 30 non-diabetic AS patients without cardiovascular disease undergoing TNF-α antagonist-infliximab therapy. OPG levels were measured immediately before and after an infliximab infusion. Correlations of OPG levels with disease activity, clinical characteristics, systemic inflammation, metabolic syndrome features, adipokines and biomarkers of endothelial activation were assessed. Changes in OPG concentration following an infusion of anti-TNF-α monoclonal antibody-infliximab were also analysed.
We found a positive correlation between OPG levels and markers of disease activity such as BASDAI and VAS spinal pain (r=0.497, p=0.01; r=0.390; p=0.04, respectively). No differences in OPG levels according to specific clinical features of the disease were seen. An inverse correlation between OPG levels and total cholesterol and LDL-cholesterol was also found (r=-0.451; p=0.02 and r=-0.411; p=0.03, respectively). A correlation between OPG and asymmetric dimethylarginine, a biomarker of endothelial cell activation, was also disclosed (r=0.533; p=0.01). No correlation between OPG level and insulin resistance was observed. An infliximab infusion did not lead to a significant reduction in OPG levels.
OPG shows a correlation with markers of disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.</description><identifier>ISSN: 0392-856X</identifier><identifier>PMID: 25190453</identifier><language>eng</language><publisher>Italy</publisher><subject>Adipokines - blood ; Adult ; Aged ; Anti-Inflammatory Agents - therapeutic use ; Antibodies, Monoclonal - therapeutic use ; Biomarkers - blood ; Endothelial Cells - drug effects ; Endothelial Cells - immunology ; Endothelial Cells - metabolism ; Female ; Humans ; Inflammation Mediators - blood ; Infliximab ; Male ; Middle Aged ; Osteoprotegerin - blood ; Severity of Illness Index ; Spondylitis, Ankylosing - blood ; Spondylitis, Ankylosing - diagnosis ; Spondylitis, Ankylosing - drug therapy ; Spondylitis, Ankylosing - immunology ; Treatment Outcome ; Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><ispartof>Clinical and experimental rheumatology, 2014-09, Vol.32 (5), p.640-646</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25190453$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Genre, Fernanda</creatorcontrib><creatorcontrib>López-Mejías, Raquel</creatorcontrib><creatorcontrib>Miranda-Filloy, José A</creatorcontrib><creatorcontrib>Ubilla, Begoña</creatorcontrib><creatorcontrib>Carnero-López, Beatriz</creatorcontrib><creatorcontrib>Palmou-Fontana, Natalia</creatorcontrib><creatorcontrib>Gómez-Acebo, Inés</creatorcontrib><creatorcontrib>Blanco, Ricardo</creatorcontrib><creatorcontrib>Rueda-Gotor, Javier</creatorcontrib><creatorcontrib>Pina, Trinitario</creatorcontrib><creatorcontrib>González-Juanatey, Carlos</creatorcontrib><creatorcontrib>Llorca, Javier</creatorcontrib><creatorcontrib>González-Gay, Miguel Á</creatorcontrib><title>Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>Osteoprotegerin (OPG) has been associated with increased risk and severity of atherosclerotic disease in the general population. Since ankylosing spondylitis (AS) is a chronic inflammatory disease associated with accelerated atherosclerosis, we aimed to assess whether OPG levels correlate with disease activity, systemic inflammation, metabolic syndrome, adipokines and biomarkers of endothelial cell activation in patients with AS undergoing TNF-α antagonist therapy.
We assessed OPG plasma concentration in 30 non-diabetic AS patients without cardiovascular disease undergoing TNF-α antagonist-infliximab therapy. OPG levels were measured immediately before and after an infliximab infusion. Correlations of OPG levels with disease activity, clinical characteristics, systemic inflammation, metabolic syndrome features, adipokines and biomarkers of endothelial activation were assessed. Changes in OPG concentration following an infusion of anti-TNF-α monoclonal antibody-infliximab were also analysed.
We found a positive correlation between OPG levels and markers of disease activity such as BASDAI and VAS spinal pain (r=0.497, p=0.01; r=0.390; p=0.04, respectively). No differences in OPG levels according to specific clinical features of the disease were seen. An inverse correlation between OPG levels and total cholesterol and LDL-cholesterol was also found (r=-0.451; p=0.02 and r=-0.411; p=0.03, respectively). A correlation between OPG and asymmetric dimethylarginine, a biomarker of endothelial cell activation, was also disclosed (r=0.533; p=0.01). No correlation between OPG level and insulin resistance was observed. An infliximab infusion did not lead to a significant reduction in OPG levels.
OPG shows a correlation with markers of disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.</description><subject>Adipokines - blood</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Biomarkers - blood</subject><subject>Endothelial Cells - drug effects</subject><subject>Endothelial Cells - immunology</subject><subject>Endothelial Cells - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Inflammation Mediators - blood</subject><subject>Infliximab</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Osteoprotegerin - blood</subject><subject>Severity of Illness Index</subject><subject>Spondylitis, Ankylosing - blood</subject><subject>Spondylitis, Ankylosing - diagnosis</subject><subject>Spondylitis, Ankylosing - drug therapy</subject><subject>Spondylitis, Ankylosing - immunology</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><issn>0392-856X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNo1kE1OwzAUhLMA0VK4AvKSTST_JE6yRBUFJEQ3RWIXvcTPqcG1Q-yCchuuwEU4E0Etq1nM981iTpI5FRVPy1y-zJLzEF4p5TKXxVky4zmraJaLefK1DhF9P_iIHQ7GkdYPA1qIGMiniVuiTEAISKCN5sPEkYBTBJ3ycYvWgD0UEI13ZNKdd6ky0GA07YS-jdYH4zoSeu_UaE00gfQTjS4GsncKh87_9ZunVfrzPRkROu9MiGTaH6AfL5JTDTbg5TEXyfPqdrO8Tx_Xdw_Lm8e054zFtC0yTmmVs0bpsmgqLqVUgI3OSl1oLbUQSBlkuq04Z1BR0HnGFC0qymkhM7FIrg-70xfvewyx3pnQorXg0O9DzfJSMioKKSb06ojumx2quh_MDoax_n9V_AK7_Xhe</recordid><startdate>20140901</startdate><enddate>20140901</enddate><creator>Genre, Fernanda</creator><creator>López-Mejías, Raquel</creator><creator>Miranda-Filloy, José A</creator><creator>Ubilla, Begoña</creator><creator>Carnero-López, Beatriz</creator><creator>Palmou-Fontana, Natalia</creator><creator>Gómez-Acebo, Inés</creator><creator>Blanco, Ricardo</creator><creator>Rueda-Gotor, Javier</creator><creator>Pina, Trinitario</creator><creator>González-Juanatey, Carlos</creator><creator>Llorca, Javier</creator><creator>González-Gay, Miguel Á</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20140901</creationdate><title>Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy</title><author>Genre, Fernanda ; López-Mejías, Raquel ; Miranda-Filloy, José A ; Ubilla, Begoña ; Carnero-López, Beatriz ; Palmou-Fontana, Natalia ; Gómez-Acebo, Inés ; Blanco, Ricardo ; Rueda-Gotor, Javier ; Pina, Trinitario ; González-Juanatey, Carlos ; Llorca, Javier ; González-Gay, Miguel Á</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-c74200951bdf87b92666daebf48f7ff6f33e01a4fc9221a90af541d0790207643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adipokines - blood</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Biomarkers - blood</topic><topic>Endothelial Cells - drug effects</topic><topic>Endothelial Cells - immunology</topic><topic>Endothelial Cells - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Inflammation Mediators - blood</topic><topic>Infliximab</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Osteoprotegerin - blood</topic><topic>Severity of Illness Index</topic><topic>Spondylitis, Ankylosing - blood</topic><topic>Spondylitis, Ankylosing - diagnosis</topic><topic>Spondylitis, Ankylosing - drug therapy</topic><topic>Spondylitis, Ankylosing - immunology</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Genre, Fernanda</creatorcontrib><creatorcontrib>López-Mejías, Raquel</creatorcontrib><creatorcontrib>Miranda-Filloy, José A</creatorcontrib><creatorcontrib>Ubilla, Begoña</creatorcontrib><creatorcontrib>Carnero-López, Beatriz</creatorcontrib><creatorcontrib>Palmou-Fontana, Natalia</creatorcontrib><creatorcontrib>Gómez-Acebo, Inés</creatorcontrib><creatorcontrib>Blanco, Ricardo</creatorcontrib><creatorcontrib>Rueda-Gotor, Javier</creatorcontrib><creatorcontrib>Pina, Trinitario</creatorcontrib><creatorcontrib>González-Juanatey, Carlos</creatorcontrib><creatorcontrib>Llorca, Javier</creatorcontrib><creatorcontrib>González-Gay, Miguel Á</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Genre, Fernanda</au><au>López-Mejías, Raquel</au><au>Miranda-Filloy, José A</au><au>Ubilla, Begoña</au><au>Carnero-López, Beatriz</au><au>Palmou-Fontana, Natalia</au><au>Gómez-Acebo, Inés</au><au>Blanco, Ricardo</au><au>Rueda-Gotor, Javier</au><au>Pina, Trinitario</au><au>González-Juanatey, Carlos</au><au>Llorca, Javier</au><au>González-Gay, Miguel Á</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2014-09-01</date><risdate>2014</risdate><volume>32</volume><issue>5</issue><spage>640</spage><epage>646</epage><pages>640-646</pages><issn>0392-856X</issn><abstract>Osteoprotegerin (OPG) has been associated with increased risk and severity of atherosclerotic disease in the general population. Since ankylosing spondylitis (AS) is a chronic inflammatory disease associated with accelerated atherosclerosis, we aimed to assess whether OPG levels correlate with disease activity, systemic inflammation, metabolic syndrome, adipokines and biomarkers of endothelial cell activation in patients with AS undergoing TNF-α antagonist therapy.
We assessed OPG plasma concentration in 30 non-diabetic AS patients without cardiovascular disease undergoing TNF-α antagonist-infliximab therapy. OPG levels were measured immediately before and after an infliximab infusion. Correlations of OPG levels with disease activity, clinical characteristics, systemic inflammation, metabolic syndrome features, adipokines and biomarkers of endothelial activation were assessed. Changes in OPG concentration following an infusion of anti-TNF-α monoclonal antibody-infliximab were also analysed.
We found a positive correlation between OPG levels and markers of disease activity such as BASDAI and VAS spinal pain (r=0.497, p=0.01; r=0.390; p=0.04, respectively). No differences in OPG levels according to specific clinical features of the disease were seen. An inverse correlation between OPG levels and total cholesterol and LDL-cholesterol was also found (r=-0.451; p=0.02 and r=-0.411; p=0.03, respectively). A correlation between OPG and asymmetric dimethylarginine, a biomarker of endothelial cell activation, was also disclosed (r=0.533; p=0.01). No correlation between OPG level and insulin resistance was observed. An infliximab infusion did not lead to a significant reduction in OPG levels.
OPG shows a correlation with markers of disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.</abstract><cop>Italy</cop><pmid>25190453</pmid><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0392-856X |
ispartof | Clinical and experimental rheumatology, 2014-09, Vol.32 (5), p.640-646 |
issn | 0392-856X |
language | eng |
recordid | cdi_proquest_miscellaneous_1586103763 |
source | Freely Accessible Journals |
subjects | Adipokines - blood Adult Aged Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal - therapeutic use Biomarkers - blood Endothelial Cells - drug effects Endothelial Cells - immunology Endothelial Cells - metabolism Female Humans Inflammation Mediators - blood Infliximab Male Middle Aged Osteoprotegerin - blood Severity of Illness Index Spondylitis, Ankylosing - blood Spondylitis, Ankylosing - diagnosis Spondylitis, Ankylosing - drug therapy Spondylitis, Ankylosing - immunology Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors |
title | Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T13%3A23%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Osteoprotegerin%20correlates%20with%20disease%20activity%20and%20endothelial%20activation%20in%20non-diabetic%20ankylosing%20spondylitis%20patients%20undergoing%20TNF-%CE%B1%20antagonist%20therapy&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=Genre,%20Fernanda&rft.date=2014-09-01&rft.volume=32&rft.issue=5&rft.spage=640&rft.epage=646&rft.pages=640-646&rft.issn=0392-856X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1586103763%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p211t-c74200951bdf87b92666daebf48f7ff6f33e01a4fc9221a90af541d0790207643%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1586103763&rft_id=info:pmid/25190453&rfr_iscdi=true |